B. Riley Reaffirms “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating restated by equities research analysts at B. Riley in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $11.00 price objective on the stock, down from their previous price objective of $14.00. B. Riley’s price target would indicate a potential upside of 154.63% from the stock’s current price.

A number of other equities analysts also recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of PDS Biotechnology in a research note on Friday, January 12th. StockNews.com downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, March 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a report on Wednesday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.33.

PDS Biotechnology Trading Up 12.2 %

Shares of NASDAQ:PDSB traded up $0.47 during trading on Thursday, reaching $4.32. 1,227,032 shares of the stock were exchanged, compared to its average volume of 865,964. PDS Biotechnology has a 12-month low of $3.61 and a 12-month high of $10.27. The firm’s 50-day moving average price is $5.26 and its 200 day moving average price is $5.10. The company has a debt-to-equity ratio of 0.96, a quick ratio of 6.21 and a current ratio of 6.21. The firm has a market cap of $134.40 million, a price-to-earnings ratio of -2.55 and a beta of 1.72.

Institutional Trading of PDS Biotechnology

Several large investors have recently modified their holdings of PDSB. Allspring Global Investments Holdings LLC purchased a new position in PDS Biotechnology in the third quarter valued at about $30,000. UBS Group AG purchased a new position in shares of PDS Biotechnology during the 3rd quarter valued at approximately $30,000. Cary Street Partners Investment Advisory LLC grew its position in shares of PDS Biotechnology by 187.7% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 6,131 shares of the company’s stock worth $31,000 after buying an additional 4,000 shares in the last quarter. BNP Paribas Arbitrage SNC bought a new stake in shares of PDS Biotechnology in the second quarter worth $37,000. Finally, Citigroup Inc. raised its holdings in PDS Biotechnology by 3,102.7% in the second quarter. Citigroup Inc. now owns 8,327 shares of the company’s stock valued at $42,000 after acquiring an additional 8,067 shares in the last quarter. 26.84% of the stock is currently owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.